Royal Free London Private Patients Unit’s Post

Hot off the press 🔥 Our meta analysis about using Hemospray for tumor-related GI bleeding in the European Journal of Gastroenterology and Hepatology (EJGH) Hemospray achieved superior immediate hemostasis vs standard endoscopic therapy (SET) ✅ The reduction in rebleeding risk and the decreased need for nonendoscopic hemostasis with Hemospray are promising✅ Hemospray showed favorable safety and reduced need for repeat interventions compared to SET✅

American College of Gastroenterology Updates Clinical Guidelines for Focal Liver Lesions 🔗 https://bit.ly/3W8DgjC This updated American College of Gastroenterology clinical guideline on focal liver lesions provides recommendations for these increasingly common findings in abdominal imaging. Two key recommendations include the use of multiphasic contrast-enhanced imaging (MRI or CT) with late arterial, portal venous, and delayed phases for focal liver lesions of unknown etiology; and discontinuing oral contraceptives or hormone-containing IUDs in patients with hepatic adenomas.

📚 We are delighted to share some highly cited papers on gastroenterology and hepatopancreatobiliary medicine that were published in the Journal of Clinical Medicine in 2023.  🔎 You may find the papers here: https://lnkd.in/dYzTGMwb #clinical #medicine #openaccess #gastroenterology #liver #pancreas #highlycitedpapers

Medicom just published a series of news articles in #Gastroenterology covering highlights presented at the #UEGWeek 2024. Read about the results of CENDAKIMAB and TACITO at https://lnkd.in/ezS6haqU. Or get your updates in 6–8 weeks from our peer-reviewed Conference Report. 𝐂𝐔𝐋𝐓𝐈𝐕𝐀𝐓𝐄: 𝐆𝐨𝐨𝐝 𝐬𝐢𝐠𝐧𝐚𝐥 𝐟𝐨𝐫 𝐞𝐭𝐫𝐚𝐬𝐢𝐦𝐨𝐝 𝐢𝐧 𝐂𝐫𝐨𝐡𝐧’𝐬 𝐝𝐢𝐬𝐞𝐚𝐬𝐞 Etrasimod was associated with favourable efficacy outcomes and tolerability in patients with moderately to severely active #Crohn’s disease (CD) in the extension period of a phase 2 trial. Placebo-controlled studies are needed to further explore the potential of etrasimod in the CD population. The selective S1P receptor modulator etrasimod was tested in the phase 2/3 CULTIVATE trial (NCT04173273) among patients with moderately to severely active CD. Prof. Geert D’Haens (Amsterdam University Medical Center, the Netherlands) presented data from the extension phase of ‘substudy A,’ a phase 2 study within the CULTIVATE trial. In this substudy, 65 participants who were refractory to at least 1 CD therapy were randomised 1:1 to etrasimod 2 mg or 3 mg daily. After 14 weeks, non-responders were re-randomised to the 2 or 3 mg arm. This analysis looked primarily at the endoscopic response after 52 weeks of therapy. An endoscopic response was defined as endoscopic remission or at least a 50% reduction in Simple Endoscopic Score (SES)-CD. In the treat-through analysis, 19.5% of the participants in the 3 mg arm and 14.3% of those in the 2 mg arm achieved an endoscopic response. Furthermore, clinical remission according to Crohn's Disease Activity Index (CDAI) was reached by 34.1% and 28.6% of the participants in the 3 mg and 2 mg arms, respectively. Also, clinical remission according to patient-reported outcome (PRO2) was observed in 36.6% and 19.0% of the participants. Continuing reading at https://lnkd.in/eQt5ya9j Medicom offers omnichannel opportunities to support your brand through advertisements and custom content in our newsletters and conference reports. For more information, please contact: 𝐍𝐋: Monique Reekers at monique.reekers@medicom-publishers.com 𝐍𝐋: Monique van Neutegem at monique.van.neutegem@medicom-publishers.com 𝐁𝐞𝐋𝐮𝐱: Mieke Verhamme at m.verhamme@medicom-publishers.com 𝐈𝐧𝐭𝐞𝐫𝐧𝐚𝐭𝐢𝐨𝐧𝐚𝐥: René Draper at r.draper@medicom-publishers.com Follow us on X for more medical content @MedicalMedicom #UEGW2024 #MedicalConference #MedicalNews #TACITO #Irritablebowelsyndrome #Crohndisease #Ulcerativecolitis #IBD

Integration of Intestinal Ultrasound and Interventional IBD…bringing together my two favourite areas in IBD Mx…highlighting potential of IUS to guide endotherapy.. published in Journal of Gastroenterology and Hepatology .. https://lnkd.in/g93s4TAS  #IUS #IIBD

Who responds best to G-POEM? "In this study of patients with gastroparesis, those with initial normal fundic meal distribution did better with G-POEM. Thus, patients with normal fundic accommodation do better than those with impaired fundic accommodation. For a good response to G-POEM, the function of the proximal stomach should be normal." https://lnkd.in/dgKuk32r https://lnkd.in/d_f5V8au GIE: Gastrointestinal Endoscopy, VideoGIE, and iGIE American Society for Gastrointestinal Endoscopy (ASGE)

Check out our latest case report on a rare complication of warfarin: skin necrosis and duodenal hematoma.

https://lnkd.in/dG456RaX Our meta-analysis published in Lancet Gastroenterology and Hepatology found that CADx did not produce benefit nor harm for the resect-and-discard strategy. * Eleven studies included (7400 diminutive polyps, 3769 patients, and 185 endoscopists) * No significant difference between the CADx-assisted and CADx-unassisted strategies for the proportion of polyps that would have avoided pathological assessment (90% [88–93], vs 90% [95% CI 85–94]). * The proportion of incorrectly predicted polyps was lower with the CADx-assisted strategy than with the CADx-unassisted strategy (12% [95% CI 7–17] vs 13% [6–20], risk ratio 0·88 [95% CI 0·79–0·98]). Cesare Hassan Tommy Rizkala Yuichi Mori Marco Spadaccini Masashi Misawa Giulio Antonelli Emanuele Rondonotti Evelien Dekker Britt BSL Houwen Oliver Pech Sebastian Baumer James Weiquan Li Daniel von Renteln Claire Haumesser Roberta Maselli Loredana Correale Maddalena Menini Alessandro Schilirò Kareem Khalaf Harsh Patel Dhruvil Radadiya Pradeep Bhandari Shin-ei Kudo Shahnaz Sultan Per Olav Vandvik Prateek Sharma Douglas Rex Farid Foroutan Alessandro Repici

Fresh out of the oven! #pepticulcer #ulcer #hospital #expertopinion #gastroenterology Proud to share our recent 📜 published in the top official “Expert Review of Gastroenterology & Hepatology”.